Dutch antitrust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers and Markets (ACM) is probing whether Biogen reserved a test for patients treated with Tysabri, its MS drug, while refusing to make the test available to patients on rival medications, such as Tyruko, a biosimilar sold by Sandoz.
Patients treated with Tysabri, Biogen’s biggest-selling medicine, must be regularly tested for the risk of developing progressive multifocal leukoencephalopathy, an infection that can be fatal or cause severe disability. Biogen developed a test for the virus and provides it free of charge exclusively to patients receiving Tysabri.
Source: statnews.com · Image: Pharmaceutical laboratory at Howard University, Washington, D.C., ca. 1900 LCCN2002695671 by African American Photographs Assembled for 1900 Paris Exposition, Public domain, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
